Rumble, Agilon Health And Oscar Health Among Stocks Moving Higher On Thursday

AI Poised to Reshape Blood Cancer Therapeutics as Investment Surges Past $2 Billion Across Leading Biotech and Pharma Players

Artificial intelligence is transforming blood cancer drug discovery and development, with over $2 billion in investment from major biotech and pharma companies. AI is reducing clinical trial timelines by up to 50%, improving patient selection, and enabling next-generation therapies like CAR-T and antibody-drug conjugates. North America leads with 40% of global market share, while Asia-Pacific emerges as a significant growth region.

National CineMedia Posts Downbeat Q2 Results, Joins Borr Drilling, AbCellera Biologics And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session

U.S. stock futures higher, Nasdaq 100 up 150 pts. National CineMedia shares down 16.4% on weak Q2 results and Captivate Holdings acquisition. Other stocks also falling in pre-market trading.

Absci shares are trading lower after the company reported worse-than-expected Q2 financial results.

Needham Reiterates Buy on Absci, Maintains $11 Price Target

Needham analyst Gil Blum reiterates Absci (NASDAQ:ABSI) with a Buy and maintains $11 price target.

JP Morgan Maintains Underweight on Agilon Health, Raises Price Target to $85

JP Morgan analyst Lisa Gill maintains Agilon Health (NYSE:AGL) with a Underweight and raises the price target from $31 to $85.

Wells Fargo Maintains Overweight on Agilon Health, Raises Price Target to $146

Wells Fargo analyst Stephen Baxter maintains Agilon Health (NYSE:AGL) with a Overweight and raises the price target from $141 to $146.